# EDGAR Filing Document

**Accession Number:** 0001691082
**File Stem:** 0000000000-25-008434
**Filing Date:** 2025-8
**Character Count:** 3839
**Document Hash:** 8166328b7ab8d0b3c63c400731481573
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008434.hdr.sgml**: 20260114

**ACCESSION NUMBER**: 0000000000-25-008434

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250812

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LB PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0001691082
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-07237

**BUSINESS ADDRESS:**
- **STREET 1:** 575 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 917-450-6581

**MAIL ADDRESS:**
- **STREET 1:** 575 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LB PHARMACEUTICALS INC.
- **DATE OF NAME CHANGE:** 20161129
**PUBLIC REFERENCE ACCESSION NUMBER**: 0000950123-24-005777

## Text-Extract

```

                                                            August 12, 2025

Heather Turner
Chief Executive Officer
LB Pharmaceuticals Inc
One Pennsylvania Plaza, Suite 1025
New York, NY 10119

       Re: LB Pharmaceuticals Inc
           Amendment No. 2 to Draft Registration Statement on Form S-1
           Submitted July 23, 2025
           CIK No. 0001691082
Dear Heather Turner:

     We have reviewed your amended draft registration statement and have the
following
comments.

        Please respond to this letter by providing the requested information
and either
submitting an amended draft registration statement or publicly filing your
registration
statement and non-public draft submissions on EDGAR. If you do not believe a
comment
applies to your facts and circumstances or do not believe an amendment is
appropriate, please
tell us why in your response.

      After reviewing the information you provide in response to this letter
and your
amended draft registration statement or filed registration statement, we may
have additional
comments.

Amendment No. 2 to Draft Registration Statement on Form S-1
Prospectus Summary
Overview, page 1

1.     You state that based on positive end-of-Phase 2 feedback from the FDA,
as well as
       historical precedent, you believe that your Phase 2 acute schizophrenia
trial may serve
       as one of the two pivotal trials required for approval of a new drug
application and
       therefore would only need a single, six-week Phase 3 trial alongside
other planned
       NDA-enabling studies for approval. Please balance this disclosure by
also stating that
       there is no guarantee that your Phase 2 trial may serve as one of the
two pivotal trials
       required which in such case you may be required to conduct two pivotal
trials for
       NDA approval.
 August 12, 2025
Page 2

Business, page 110

2.     We note your use of p-values throughout this section regarding your
product
       candidate LB-102. At first use, please provide a brief explanation of
the disclosed p-
       value and how it is used to measure statistical significance.
        Please contact Christine Torney at 202-551-3652 or Angela Connell at
202-551-3426
if you have questions regarding comments on the financial statements and
related
matters. Please contact Doris Stacey Gama at 202-551-3188 or Laura Crotty at
202-551-7614
with any other questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Brandon Fenn, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._